Journal of Glaucoma
04/26/2002
By Mark Moran
Brimonidine-purite 0.15% and 0.2%, appears to decrease intraocular pressure comparably to brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Jay Katz, MD, of the Brimonidine-Purite Study Group, Wills Eye Hospital, Philadelphia, Pennsylvania, United States headed this 12-month, randomized, multi-center study of the two drugs–with brimonidine-Purite tested at two different concentrations. The group found that brimonidine-Purite 0.15% showed the most favorable safety and tolerability profile and a reduced incidence of allergic conjunctivitis. It also showed a better satisfaction and comfort rating.
There were no statistically significant differences in mean intraocular pressure or mean changes from baseline intraocular pressure (at peak or trough) among groups receiving either drug. Difference in mean intraocular pressure between patients receiving brimonidine-purite-0.15% and those receiving brimonidine-0.2% treatment group was less than 1 mmHg.
The relative percent difference in allergic conjunctivitis was 41% lower in the brimonidine-purite 0.15% group compared with the brimonidine 0.2% group. The comfort and satisfaction rating significantly favored brimonidine-Purite 0.15%, he reports.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!